
Commentary|Videos|December 9, 2024
Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma
Author(s)David M. Siegel, MD, PhD
David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.
Advertisement
David Samuel Dicapua Siegel, MD, chief, Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, discusses preliminary findings from the phase 1/2 CA057-003 trial (NCT05372354) evaluating the novel agent mezigdomide for patients with relapsed or refractory multiple myeloma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































